glypressin 1 mg
ferring legemidler as - terlipressindiacetat - injeksjonsvæske, oppløsning - 1 mg
albumin baxalta 50 g/ l
baxalta innovations gmbh - albumin, humant - infusjonsvæske, oppløsning - 50 g/ l
flexbumin 200 g/ l
baxalta innovations gmbh - albumin, humant - infusjonsvæske, oppløsning - 200 g/ l
cabometyx
ipsen pharma - cabozantinib (s)-malate - carcinoma, renal cell; carcinomas, hepatocellular - antineoplastiske midler - renal cell carcinoma (rcc)cabometyx is indicated as monotherapy for the treatment of advanced renal cell carcinoma (rcc):in treatment-naïve adults with intermediate or poor risk,in adults following prior vascular endothelial growth factor (vegf)-targeted therapy. cabometyx, in combination with nivolumab, is indicated for the first-line treatment of advanced renal cell carcinoma in adults. hepatocellular carcinoma (hcc)cabometyx is indicated as monotherapy for the treatment of hepatocellular carcinoma (hcc) in adults who have previously been treated with sorafenib.
cyramza 10 mg/ ml
orifarm as - ramucirumab - konsentrat til infusjonsvæske, oppløsning - 10 mg/ ml
albunorm 50 g/ l
octapharma (2) - albumin, humant - infusjonsvæske, oppløsning - 50 g/ l
albunorm 200 g/ l
octapharma (2) - albumin, humant - infusjonsvæske, oppløsning - 200 g/ l